Amphastar Pharmaceuticals Inc logo

AMPH - Amphastar Pharmaceuticals Inc Share Price

$17.3 -0.1  -0.3%

Last Trade - 9:00pm

Mid Cap
Market Cap £600.5m
Enterprise Value £591.3m
Revenue £253.8m
Position in Universe 3010th / 6851
Unlock AMPH Revenue
Relative Strength (%)
1m -9.35%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -23.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
251.5 255.2 240.2 294.7 322.4 349.8 416.7 475.8 +6.8%
-80.7 +44.9
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Amphastar Pharmaceuticals Inc revenues increased 9% to$349.8M. Net income decreased 97% to $1.4M. Revenuesreflect Pharmaceutical segment increase of 10% to $331.4M,United States segment increase of 9% to $333.1M, Chinasegment increase from $1.5M to $3.2M. Net income was offsetby Other income (expense), net decrease from $59.4M(income) to $6.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


AMPH Revenue Unlock AMPH Revenue

Net Income

AMPH Net Income Unlock AMPH Revenue

Normalised EPS

AMPH Normalised EPS Unlock AMPH Revenue

PE Ratio Range

AMPH PE Ratio Range Unlock AMPH Revenue

Dividend Yield Range

AMPH Dividend Yield Range Unlock AMPH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AMPH EPS Forecasts Unlock AMPH Revenue
Profile Summary

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated May 19, 2004
Public Since June 25, 2014
No. of Shareholders: 143
No. of Employees: 1,980
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite , S&P 600 Small Cap , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 47,718,003
Free Float (0.0%)
Eligible for
AMPH Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AMPH
Upcoming Events for AMPH
Tuesday 8th June, 2021 Estimate
Amphastar Pharmaceuticals Inc Annual Shareholders Meeting
Frequently Asked Questions for Amphastar Pharmaceuticals Inc
What is the Amphastar Pharmaceuticals Inc share price?

As of 9:00pm, shares in Amphastar Pharmaceuticals Inc are trading at $17.3, giving the company a market capitalisation of £600.5m. This share price information is delayed by 15 minutes.

How has the Amphastar Pharmaceuticals Inc share price performed this year?

Shares in Amphastar Pharmaceuticals Inc are currently trading at $17.3 and the price has moved by 7.16% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Amphastar Pharmaceuticals Inc price has moved by -27.26% over the past year.

What are the analyst and broker recommendations for Amphastar Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Amphastar Pharmaceuticals Inc, there are there are currently 1 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Amphastar Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Amphastar Pharmaceuticals Inc next release its financial results?

Amphastar Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Amphastar Pharmaceuticals Inc dividend yield?

Amphastar Pharmaceuticals Inc does not currently pay a dividend.

Does Amphastar Pharmaceuticals Inc pay a dividend?

Amphastar Pharmaceuticals Inc does not currently pay a dividend.

When does Amphastar Pharmaceuticals Inc next pay dividends?

Amphastar Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Amphastar Pharmaceuticals Inc shares?

To buy shares in Amphastar Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Amphastar Pharmaceuticals Inc?

Shares in Amphastar Pharmaceuticals Inc are currently trading at $17.3, giving the company a market capitalisation of £600.5m.

Where are Amphastar Pharmaceuticals Inc shares listed? Where are Amphastar Pharmaceuticals Inc shares listed?

Here are the trading details for Amphastar Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AMPH
What kind of share is Amphastar Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Amphastar Pharmaceuticals Inc is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Amphastar Pharmaceuticals Inc share price forecast 2021?

Shares in Amphastar Pharmaceuticals Inc are currently priced at $17.3. At that level they are trading at 22.19% discount to the analyst consensus target price of 0.00.

Analysts covering Amphastar Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.943 for the next financial year.

How can I tell whether the Amphastar Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amphastar Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -31.23%. At the current price of $17.3, shares in Amphastar Pharmaceuticals Inc are trading at -10.26% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Amphastar Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Amphastar Pharmaceuticals Inc.

Who are the key directors of Amphastar Pharmaceuticals Inc?

Amphastar Pharmaceuticals Inc's management team is headed by:

Richard Prins - LED
Jack Zhang - PRE
Mary Luo - CHM
William Peters - CFO
Diane Gerst - DRC
Richard Koo - IND
Howard Lee - IND
Floyd Petersen - IND
Rong Zhou - EVP
Jacob Liawatidewi - SVP
Who are the major shareholders of Amphastar Pharmaceuticals Inc?

Here are the top five shareholders of Amphastar Pharmaceuticals Inc based on the size of their shareholding:

Applied Physics & Chemistry Laboratories, Inc. Corporation
Percentage owned: 14.74% (7.03m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 13.12% (6.26m shares)
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund
Percentage owned: 6.48% (3.09m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 5.2% (2.48m shares)
iShares Core S&P Small-Cap ETF Mutual Fund
Percentage owned: 5.14% (2.45m shares)
Similar to AMPH
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.